| Literature DB >> 31409417 |
Nina Van Goethem1,2, Tine Descamps3, Brecht Devleesschauwer3,4, Nancy H C Roosens5, Nele A M Boon3, Herman Van Oyen3,6, Annie Robert7.
Abstract
BACKGROUND: Next-generation sequencing (NGS) is increasingly being translated into routine public health practice, affecting the surveillance and control of many pathogens. The purpose of this scoping review is to identify and characterize the recent literature concerning the application of bacterial pathogen genomics for public health practice and to assess the added value, challenges, and needs related to its implementation from an epidemiologist's perspective.Entities:
Keywords: Bacterial infections; Epidemiology; Genomics; Next-generation sequencing; Public health practice; Scoping review; Whole-genome sequencing
Mesh:
Year: 2019 PMID: 31409417 PMCID: PMC6692930 DOI: 10.1186/s13012-019-0930-2
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Fig. 1Focus of the scoping review on pathogen genomics for public health practice. Different domains in the field of infectious diseases require access to the same pathogen genomic data. Whole-genome sequencing (WGS) has the ability to inform and improve individual patient care, by identifying the species, determining its pathogenic potential, and testing its susceptibility to antimicrobial drugs. WGS also provides data for public health surveillance about the relatedness of the pathogen to other strains to investigate transmission routes, monitor trends over time, and allow the identification and control of outbreaks and new threats. Research is a knowledge driver providing reference data, methods, and a deeper understanding about the underlying biological mechanisms to the other domains. The focus of this scoping review is on the use of WGS as a public health tool, i.e., at the level of the population
Fig. 2Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
Characteristics of included studies (Jan 2015 to Sep 2018: n = 275)
| Study characteristic | No. of studies (Jan 2015 to Sep 2018) | ||
|---|---|---|---|
| Outbreak investigations ( | Control-oriented surveillance ( | Strategy-oriented surveillance ( | |
| Country¥,* | |||
| USA and Canada | 42 | 7 | 16 |
| UK and Ireland | 33 | 13 | 15 |
| Australia and New Zealand | 19 | 3 | 7 |
| Germany | 14 | 2 | 4 |
| Denmark | 9 | 4 | 0 |
| France | 5 | 2 | 2 |
| Setting¥ | |||
| Community | 94 | 23 | 47 |
| Institutional (hospital, school, nursery, etc.) | 73 | 21 | 25 |
| Time orientation of NGS analyses¥ | |||
| Retrospective | 97 | 18 | 59 |
| Quasi-real time | 58 | 0 | 0 |
| Prospective | 11 | 25 | 11 |
| Level of implementation of NGS analyses¥ | |||
| Proof-of-concept | 57 | 27 | 8 |
| Used to address a specific public health problem | 100 | 10 | 61 |
| Implemented into routine public health | 14 | 6 | 2 |
| Sampling fraction of NGS analyses | |||
| All available samples | 57 | 25 | 21 |
| Subset of available samples (complementary) | 107 | 16 | 48 |
| Pathogens¥ | |||
| | 15 | 10 | 13 |
| Multidrug-resistant Gram-negative bacteria | 27 | 4 | 12 |
| Vancomycin-resistant Enterococci (VRE) | 5 | 6 | 0 |
| | 5 | 1 | 2 |
| | 8 | 0 | 6 |
| | 13 | 4 | 1 |
| | 1 | 2 | 2 |
| | 33 | 5 | 8 |
| Shiga toxin-producing | 10 | 4 | 1 |
| | 5 | 0 | 0 |
| | 10 | 0 | 1 |
| | 14 | 6 | 5 |
| | 6 | 0 | 14 |
| Others | 13 | 1 | 6 |
¥One study can be assigned to multiple categories
*Non-exhaustive list
Study aims (applications of NGS) of included studies (Jan 2015 to Sep 2018: n = 275)
| Study aim(s) | |
|---|---|
| Outbreak investigations ( | |
| Source tracing | 78 |
| Identify transmission routes | 85 |
| Inform outbreak management: feedback on key phenotypic attributes | 11 |
| Control-oriented surveillance ( | |
| Understand transmission dynamics (identify transmission networks/clusters) | 15 |
| Early outbreak detection | 23 |
| Overview of circulating strains to identify the emergence of new threats | 12 |
| Strategy-oriented surveillance ( | |
| Understand transmission dynamics to develop prevention strategies | 21 |
| Overview of circulating strains (long-term trends) | 38 |
| Impact assessment of prevention and control programs | 29 |
| Identification of risk factors and risk groups | 6 |
One study can have multiple study aims
Fig. 3Integration of multiple data types. The anticipated workflow of infection prevention and control includes the following: (1) samples are obtained from cases infected with a certain pathogen, as well as from other sources such as the environment, food, and/or animals following the One Health approach; (2) pathogens are isolated, and information concerning the biological characteristics is obtained through classical microbiological testing. Phenotypic tests are still required to feed databases and confirm genotype-phenotype associations. Culturing steps (isolation) are often preceding genome sequencing; however, sequencing directly from clinical samples is also possible using culture-independent methods (metagenomics); (3) high-throughput sequence data is generated (other -omics technologies such as transcriptomics, proteomics, and metabolomics can complement the genomic information); (4) relationships among isolates and specific characteristics are inferred based on sequence information obtained through bioinformatics tools; (5) to come to a meaningful outcome (i.e., transmission chains, cluster identification, source tracing, key phenotypic attributes), the genomic evidence is combined with epidemiological metadata (time, place, exposures, etc.) from field epidemiological investigations, clinical data obtained through the healthcare system, biological characteristics obtained through classic microbiological methods, and big data on natural and social factors. Finally, infection prevention and control measures can be conducted on the basis of this aggregated information